Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2366 • 2019 ACR/ARP Annual Meeting
Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Barton Jones ², Allison Petrilla ², Leticia Ferri ³, Xue Han ³ and Kaleb Michaud ⁴, ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA experienced an increase in the whole-body insulin sensitivity and a reduction in HbA1c levels from treatment with abatacept, which is a…
Abstract Number: 2392 • 2019 ACR/ARP Annual Meeting
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Takayasu Ando¹, Takeshi Suzuki ², Yutaka Gotou ¹ and Kimito Kawahata ³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: In daily practice, our rheumatologist has experienced different clinical feature of elderly-onset rheumatoid arthritis (EORA) compared with younger-onset RA (YORA). In EORA patients, serological…
Abstract Number: 2793 • 2019 ACR/ARP Annual Meeting
Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives
Elizabeth Salt¹, Mary Kay Rayens ², Leslie Crofford ³ and Jamie Studts ², ¹University of Kentucky, Lexington, KY, ²University of Kentucky, Lexington, ³Vanderbilt University, Nashville
Background/Purpose: An estimated 11% to 33% of persons taking methotrexate for rheumatoid arthritis (RA) are reported to be at least moderately intolerant to this medication.…
Abstract Number: 2890 • 2019 ACR/ARP Annual Meeting
The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study
Mark Tatangelo¹, George Tomlinson ², Edward Keystone ³, Michael Paterson ⁴, Nick Bansback ⁵ and Claire Bombardier ⁶, ¹University of Toronto, Toronto, Canada, ²University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁴Institute for Clinical Evaluative Sciences, Toronto, Canada, ⁵University of British Columbia, Vancouver, Canada, ⁶Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The direct and indirect effects of rheumatoid arthritis (RA) are difficult to measure in observational studies because: (1) The inflammatory effects of RA are…
Abstract Number: 2822 • 2019 ACR/ARP Annual Meeting
Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women
Jeffrey Sparks¹, Susan Malspeis ¹, Jill Hahn ², Andrea Roberts ², Laura Kubzansky ² and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard School of Public Health, Boston, MA
Background/Purpose: Depression is associated with elevated systemic inflammation and risk of several chronic diseases including lupus, psoriasis, and inflammatory bowel disease. However, the association between…
Abstract Number: 40 • 2019 ACR/ARP Annual Meeting
Inflammation and Neuronal Growth Factors in Rheumatoid Arthritis
Caroline Wasén¹, Lovisa Leifsdottir ², Roda Abdalla ¹, Lina Juzokaite ¹, Karin Andersson ¹, Malin Erlandsson ¹, Marie Kalm ³ and Maria Bokarewa ¹, ¹Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gotheburg, Sweden, ³hDepartment of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Depression and cognitive impairment are frequently reported in rheumatoid arthritis (RA). We have recently presented that reduced hippocampus volume may be linked to functional…
Abstract Number: 124 • 2019 ACR/ARP Annual Meeting
Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis
Maria-Eugenia Miranda-Carus¹, Paula Fortea-Gordo ², Laura Nuño ³, Alejandro Villalba ⁴, Maria-Jose Santos-Bornez ², Diana Peiteado ², Irene Monjo ¹ and Alejandro Balsa ⁵, ¹FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ²FIBHULP-IdiPAZ-Hospital La Paz, Madrid, Spain, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ⁴FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, ⁵Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain
Background/Purpose: Circulating CD4 T cells that express CXCR5 together with PD-1 and/or ICOS are considered as counterparts of bona fide Tfh cells and function as…
Abstract Number: 208 • 2019 ACR/ARP Annual Meeting
Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)
Patricia Katz¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of California, San Francisco, san francisco, CA, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Sleep disturbances (SD) are reported to be common in RA but relatively few studies have addressed the issue. We examined the frequency and severity…
Abstract Number: 414 • 2019 ACR/ARP Annual Meeting
Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients
Vivek Joseph ¹, Swetha Vontela ², Surjeet Dheer³, Molly Weinberg ⁴, Zuhayr Haq ² and Arundathi Jayatilleke ⁵, ¹Drexel University, PHILADELPHIA, PA, ²Drexel University, Philadelphia, ³Mercy Catholic Medical Center, Philadelphia, ⁴Drexel University, Philadlephia, ⁵Drexel, Philadelphia, PA
Background/Purpose: With the advent of biologic therapy for RA, the American College of Rheumatology advocates a treat to target (TTT) approach in the treatment of…
Abstract Number: 457 • 2019 ACR/ARP Annual Meeting
Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity
Yoko Wada¹, Masanori Sudo ², Daisuke Kobayashi ², Takeshi Kuroda ³ and Masaaki Nakano ⁴, ¹Niigata Rinko Hospital, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ³Health administration office, Niigata University, Niigata, Niigata, Japan, ⁴School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Altered body composition is a common feature of patients with rheumatoid arthritis (RA), up to two-thirds of affected patients showing loss of muscle mass…
Abstract Number: 496 • 2019 ACR/ARP Annual Meeting
Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort
McKayla Muse¹, Ly Tran ¹, Carla J. Guthridge ², Nancy Redinger ² and Judith James ³, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Anti-CCP antibodies are present in the serum of healthy individuals who are at risk of developing RA and serve as an important tool for…
Abstract Number: 540 • 2019 ACR/ARP Annual Meeting
Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar
Lisa Baganz¹, Anja Strangfeld ², Peter Herzer ³, Andreas Krause ⁴, Hans-Peter Tony ⁵ and Angela Zink ⁶, ¹German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center (DRFZ), Berlin, Germany, ³Scientific Advisory Board, München, Germany, ⁴Immanuel Krankenhaus, Berlin, Germany, ⁵Department of Rheumatology/Clinical Immunology, University Hospital, Wuerzburg, Germany, Würzburg, Germany, ⁶German Rheumatism Research Centre and Charité University medicine, Berlin, Germany
Background/Purpose: In Germany, the first etanercept biosimilar was licensed in 2016. In contrast to other European countries there is no uniform recommendation for the prescription…
Abstract Number: 843 • 2019 ACR/ARP Annual Meeting
High Lung Attenuation Measured with Quantitative Densitometry as a Surrogate Marker for Interstitial Lung Disease in RA: Association with Anti-CCP, Smoking, and Absence of Shared Epitope
Michail Alevizos¹, Sonye Danoff ², Dimitrios Pappas ¹, David Lederer ³, Cheilonda Johnson ⁴, Elana Bernstein ⁵, Joan Bathon ⁵ and Jon Giles ⁵, ¹Division of Rheumatology, Columbia University, New York, ²Division of Pulmonary & Critical Care Medicine, Johns Hopkins University, Baltimore, ³Division of Pulmonary & Critical Care Medicine, Columbia University, New York, ⁴Division of Pulmonary & Critical Care Medicine, University of Pennsylvania, Philadelphia, ⁵Division of Rheumatology, Columbia University, New York, NY
Background/Purpose: Risk factors for rheumatoid arthritis-associated interstitial lung disease (RA-ILD), a significant cause of morbidity and mortality, are poorly understood. RA-ILD detection is limited by…
Abstract Number: 974 • 2019 ACR/ARP Annual Meeting
Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Garth Ringheim¹, Matthew Wampole ¹ and Kinsi Oberoi ¹, ¹Clarivate Analytics, Philadelphia, PA
Background/Purpose: Clinical development of BTK/Tec family kinase inhibitors for treating autoimmune diseases has lagged that of their successful application in oncology. The lack of selective…
Abstract Number: 1177 • 2019 ACR/ARP Annual Meeting
Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare
Richard Bell¹, Homaira Rahimi ², Alicia Lieberman ², Ronald Wood ², Edward Schwarz ³ and Christopher Ritchlin ⁴, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester, ³University of Rochester, Rochester, NY, ⁴Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Near infrared (NIR) imaging of indocyanine green (ICG) in rheumatoid arthritis (RA) models identified abnormal lymphatic vessel (LV) function, which can be quantified as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].